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Abstract 
Background: Induced pluripotent stem cells (iPSC) possess an enormous potential as both, scientific and therapeu‑
tic tools. Their application in the regenerative medicine provides new treatment opportunities for numerous diseases, 
including type 1 diabetes. In this work we aimed to derive insulin producing cells (IPC) from iPS cells established in 
defined conditions.
Methods: We optimized iPSC generation protocol and created pluripotent cell lines with stably integrated PDX1 and 
NKX6.1 transgenes under the transcriptional control of doxycycline‑inducible promoter. These cells were differentiated 
using small chemical molecules and recombinant Activin A in the sequential process through the definitive endo‑
derm, pancreatic progenitor cells and insulin producing cells. Efficiency of the procedure was assessed by quantitative 
gene expression measurements, immunocytochemical stainings and functional assays for insulin secretion.
Results: Generated cells displayed molecular markers characteristic for respective steps of the differentiation. The 
obtained IPC secreted insulin and produced C‑peptide with significantly higher hormone release level in case of the 
combined expression of PDX1 and NKX6.1 induced at the last stage of the differentiation.
Conclusions: Efficiency of differentiation of iPSC to IPC can be increased by concurrent expression of PDX1 and 
NKX6.1 during progenitor cells maturation. Protocols established in our study allow for iPSC generation and derivation 
of IPC in chemically defined conditions free from animal‑derived components, which is of the utmost importance in 
the light of their prospective applications in the field of regenerative medicine.
Keywords: Defined culture conditions, Diabetes, Differentiation, Induced pluripotent stem cells, Insulin producing 
cells, NKX6.1, PDX1, Reprogramming
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Background
Type 1 diabetes (T1D) is one of the most frequent 
chronic autoimmune diseases diagnosed among juve-
niles, and its global incidence continues to rise [1]. This 
condition is characterized by pancreatic beta cell dam-
age leading to insufficient insulin production and altered 
carbohydrate metabolism. It develops at an early age and 
requires constant treatment, which generates substan-
tial costs and lowers quality of life. Commonly, therapy 
of type 1 diabetes is based on supplementation of defi-
cient hormone in form of regular injections. However, 
this method does not address the cause of the disease, 
regarded as a lack of functional intrinsic mechanisms 
providing carbohydrate homeostasis.
Pancreatic islet transplantation is another approach to 
T1D treatment. Its application is however limited due to 
complex medical procedure and shortage in the number 
of islets donors. Moreover, it is not a permanent solu-
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procedures eventually need to receive insulin injections 
due to the destruction of the graft by the immune system 
[2].
A concept of a therapy based on differentiated induced 
pluripotent stem cells (iPSC) raises great promises in the 
field of T1D treatment. These cells are generated from 
somatic cells by forced expression of transcription factors 
characteristic for embryonic stem cells [3]. Numerous 
investigations have been conducted to confirm resem-
blance between iPSC and embryonic stem cells (ESC) 
isolated from the inner cell mass of developing embryo 
[4, 5].
These cells are characterized by features of great 
importance in terms of disease treatment, such as the 
fact that they are obtained from patient’s own cells. This 
trait eliminates risk of potential stem cell-based graft 
rejection [6].
A number of research teams are focused on genera-
tion of functional insulin producing cells (IPC) that could 
replace damaged beta cells. Their approaches are based 
on mimicking of in  vivo mechanisms underlying pan-
creas development [7, 8]. However, at present there is no 
sufficient comprehension of the molecular backgrounds 
of pancreatic organogenesis, which originates from com-
plexity of this process and difficulties in exploring it in 
humans. Therefore, despite of numerous attempts, an 
efficient protocol of functional insulin producing cells for 
clinical applications has not been established [9].
The main obstacle is caused by heterogeneity of 
obtained cells as well as their functionality, which typi-
cally results in production of other pancreatic hormones 
or inadequate response to changing glucose concentra-
tion in  vitro [10–12]. Thus, the on-going research on 
generation of clinically applicable insulin producing cells 
continues all around the world.
In this work an attempt has been made to generate 
insulin producing cells from induced pluripotent stem 
cells by means of chemical differentiation and induction 
of certain transgene expression [13]. For the purpose of 
the study, selected genes are PDX1 (Pancreatic and Duo-
denal Homeobox  1) and NKX6.1 (Homeobox Protein 
Nkx6.1), as their expression seems to be critical in pan-
creatic organogenesis, which was reported in numerous 
studies [14, 15]. Moreover, these factors act on different 
stages of pancreatic development, and as indicated in 
several investigations, disturbances of their expression 
result in altered organ structure or functional activity of 
the pancreas [16].
Considering prospective clinical application, it is essen-
tial to obtain these cells in conditions that will ensure 
patient’s safety. Therefore, attempts have been made 
to establish protocols and defined conditions of iPSC 
generation, culture and differentiation. The framework of 
the experimental design is shown in Fig. 1.
In order to investigate the influence of over-expression 
of PDX1 and NKX6.1 factors on generation of insulin 
producing cells in  vitro, genetically engineered iPS cell 
lines with introduced sequences of PDX1-VP16, NKX6.1 
and combination of thereof under control of inducible 
promoter were established. Moreover, the expression was 
induced on selected stages of differentiation process.
This work focuses on three aspects. Firstly, reprogram-
ming of selected somatic cell lines to iPSC in defined con-
ditions. Secondly, generation of definitive endoderm cells 
(DE) from iPSC by activation of TGFβ signalling pathway 
and inhibition of GSK3β in presence of either human or 
bovine serum or combination of defined factors. And 
finally, we analysed the influence of PDX1 and NKX6.1 
transcription factors on the process of differentiation and 
maturation of insulin producing cells.
Methods
Reagents
Unless specified otherwise, all chemicals were from 
Sigma-Aldrich (St. Louis, MO, USA). Cell culture media 
were purchased from Life Technologies (Carlsbad, CA, 
USA). Restriction endonucleases, polymerases and DNA 
modifying enzymes were from New England Biolabs 
(Ipswitch, MA, USA).
DNA constructs
To create pENTR/zeo-Pdx1-VP16 vector, Pdx1 coding 
region in frame with VP16 trans-acting coding sequence 
from the Herpes Simplex virus was synthesised by 
GeneArt AG (Regensburg, Germany) as a String™ DNA, 
and amplified with Q5 DNA polymerase using Pdx1-
VP16 attB1 and Pdx1-VP16 attB2 oligonucleotides. The 
PCR product was shuttled with Gateway BP Clonase 
II (Life Technologies) into pDONR/zeo plasmid (Life 
Technologies) resulting in pENTR/zeo-Pdx1-VP16 con-
struct. The sequence was confirmed by DNA sequencing 
with M13 Fwd (−20) and M13 Rev primers. To generate 
pENTR/zeo-Nkx6.1 construct, the total RNA was iso-
lated from HEK293T cells and reverse-transcribed with 
random hexamer primers and M-MuLV reverse tran-
scriptase. Nkx6.1 coding sequence was amplified from 
the cDNA with Q5 DNA polymerase with Nkx6.1 attB1 
and Nkx6.1 attB2 primers and transferred into pDONR/
zeo plasmid by means of the Gateway BP Clonase II 
enzyme to create pENTR/zeo-Nkx6.1 vector. In order to 
generate pLVX-TRE3G-DEST construct, pLVX-TRE3G-
IRES plasmid (Clontech, Mountain View, CA, USA) was 
digested with EcoRI and BamHI restriction enzymes and 
filled with T4 DNA polymerase. The vector was isolated 
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from the agarose gel with QIAquick DNA Gel Extrac-
tion Kit (Qiagen, Venlo, Limburg, The Netherlands) and 
ligated using T4 DNA ligase with Gateway Rf.A cassette 
(Life Technologies) that encompasses attR1 and attR2 
recombination sequences, chloramphenicol resistance 
gene and ccdB negative selection marker. The correct ori-
entation of the ligated insert was determined by restric-
tion digest and DNA sequencing using primers Gateway 
1 and Gateway 2. The transfer of Pdx1-VP16 fragment 
from the ENTRY construct into the final pLVX-TRE3G-
Pdx1-VP16 vector was done using Gateway LR Clonase 
II enzyme (Life Technologies). The pLVX-TRE3G-Nkx6.1 
plasmid was created by shuttling of Nkx6.1 sequence 
from the pENTR/zeo-Nkx6.1 vector into pLVX-TRE3G-
DEST with Gateway LR Clonase II. The identity of the 
last two vectors was determined by restriction digest 
and DNA sequencing using pLVX-TRE3G Fwd and 
pLVX-TRE3G Rev primers. To generate pCXB-EmGFP 
vector, EmGFP coding sequence was PCR-amplified 
from pRSET-EmGFP plasmid (Life Technologies) with 
FP attB1 and FP attB2 primers. Obtained PCR product 
was shuttled into pDONR/zeo plasmid with application 
of Gateway BP Clonase II enzyme, resulting in pENTR/
zeo-EmGFP construct. The transfer of the EmGFP frag-
ment from the ENTRY construct into final expression 
vector was done by with Gateway LR Clonase II enzyme 
and pCXB-DEST plasmid (described in [17]). DNA 
sequences of oligonucleotides used for cloning purposes 
are included in Additional file 1: Table S1.
Generation and culture of induced pluripotent stem cells
Unless stated otherwise, iPS cells were generated as 
described previously [17]. Briefly, cells were seeded 
on Geltrex-coated cell culture plates and incubated 
overnight in a suitable primary medium. On the next day, 
cells were transfected with five episomal plasmids (pCE-
hOct3/4, pCE-hSK pCE-hUL, pCE-mp53DD, and pCXB-
EBNA1). After a 24-h incubation, medium was replaced 
with TeSR-E7 medium (StemCell Technologies), and the 
transfection was repeated. The medium was changed 
every other day for 14 days. After that, culture medium 
was replaced with Essential 8 and cells were cultivated 
until iPSC colonies started to appear. Then, they were 
transferred onto a new, Geltrex-coated culture dishes, 
expanded and maintained in Essential 8 medium.
Cell culture
iPS cells derived from human fibroblasts, established as 
described earlier [17], were cultured in low oxygen con-
ditions (5% O2/5% CO2), in chemically defined Essen-
tial 8 medium on cell culture plates coated with Geltrex 
(20  μg/cm2) or recombinant Vitronectin (0.5  μg/cm2). 
Cells were passaged twice a week when they reached 
60–70% confluence. Pluripotent cells were incubated in 
Essential 8 medium supplemented with 10  μM Y-27632 
for 1  h before passaging and colony expansion. Cells 
were dissociated with 0.5 mM EDTA in ion-free PBS for 
5–8  min at room temperature. Afterwards, EDTA solu-
tion was removed, and the process of cell separation was 
terminated by addition of Essential 8 medium. Clumps 
of cells were then transferred into fresh culture ves-
sels coated with Geltrex or Vitronectin. Renal epithelial 
cells were isolated from urine samples according to the 
protocol described previously [18]. Cells were cultured 
on gelatin-coated cell culture plates and maintained 
in REBM medium supplemented with REGM Single-
Quot Kit (Lonza, Basel, Switzerland). HFF-1 (neonatal 
human foreskin fibroblasts) and HEK293T cell lines were 
Fig. 1 The outline of the differentiation procedure of iPSC into insulin producing cells. Schematic representation of the procedure used for differen‑
tiation of iPS cells to insulin producing cells. Arrows indicate time points of induction of transcription factors expression with doxycycline (DOX). The 
experimental framework consisted of four stages: culture of iPS cells, generation of definitive endoderm cells, formation of pancreatic progenitor 
cells and development of mature insulin producing cells. The diagram presents composition of the media used at each step
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obtained from ATCC (Manassas, VA, USA). Cells were 
cultured in DMEM supplemented with 10% FBS. HeLa 
cells were purchased from DSMZ (Braunschweig, Ger-
many) and cultured in DMEM medium supplemented 
with 10% FBS. In addition, all the abovementioned cell 
culture media contained penicillin (100  U/mL), strep-
tomycin (100 µg/mL), amphotericin B (0.25 µg/mL) and 
2.5  µg/mL of Plasmocin (InvivoGen, San Diego, CA, 
USA).
Coating agents
Geltrex™ hESC-qualified basement membrane matrix 
and Coating Matrix Kit (human, recombinant Colagen 
I) were purchased from Life Technologies. Vitronec-
tin XF™, full-length human recombinant protein was 
obtained from STEMCELL Technologies (Vancouver, 
BC, Canada). Laminin-511 and Laminin-521 was pur-
chased from BioLamina AB (Sundbyberg, Sweden). 
Fibronectin from human plasma, Laminin from Engel-
breth-Holm-Swarm murine sarcoma basement mem-
brane, Collagen IV from human placenta and porcine 
Gelatin were from Sigma-Aldrich. All of the protein coat-
ing agents were diluted in DMEM/F12 basal medium to 
desired concentrations, applied on the surfaces of cell 
culture vessels and incubated for 1 h at 37 °C.
Preparation of L64‑PEI copolymer
L64-PEI copolymer was synthesised as reported earlier 
[19, 20] with minor modifications. Briefly, 2  g of plu-
ronic-L64 PEG-PPG-PEG block polymer, with average 
molecular weight of 2900 Da, was desiccated in a vacuum 
dryer (VacuCell 22, MMM Medcenter, Germany) at 40 °C 
overnight and activated with threefold molar excess of 
1,1′-carbonyldiimidazole (CDI) in 10  mL of anhydrous 
acetonitrile. After 3  h of incubation on shaker platform 
at room temperature, the reaction mixture was diluted 
with equal volume of deionized water and dialyzed 
against 10% ethanol/H2O for 24 h using 1 kDa molecular 
weight cut-off cellulose membrane tube. Following dialy-
sis, the activated Pluronic-L64 derivate was desiccated in 
a vacuum dryer overnight at 40 °C and dissolved in 20% 
ethanol/H2O. The activated polymer was conjugated with 
fivefold molar excess of polyethyleneimine (PEI, molecu-
lar weight 1200 Da) and the resulting solution was stirred 
overnight at room temperature. In order to remove unin-
corporated PEI, the reaction mixture was dialyzed for 
48 h at room temperature against deionized water using 
3.5  kDa cut-off cellulose membrane. To separate conju-
gated polymer from unreacted Pluronic-L64, the reaction 
product was processed with HiTrap SP cation exchange 
chromatography column (GE Healthcare Bio-Sciences, 
Uppsala, Sweden), washed with five column volumes 
of the 10% ethanol/H2O and eluted with 500 mM citric 
acid. Following 24 h of dialysis with 3.5 kDa MWCO cel-
lulose membrane against 20% ethanol/H2O, the reaction 
product was desiccated for 24 h in vacuum dryer, heated 
at 65  °C in order to remove residual DNAse activity, 
weighted and dissolved in nuclease-free water.
Production of lentiviral vectors
Lentiviral particles were generated by the simultaneous 
transient transfection of HEK293T cells with packaging 
plasmid (pLV-HELP), envelope plasmid (pLV-iVSV-G, for 
pseudotyping viral particles with pantropic VSV-G pro-
tein) and the transfer vector carrying the gene of interest. 
Packaging and envelope plasmids were purchased from 
InvivoGen as a part of LENTI-Smart kit, a 2nd generation 
lentiviral system. HEK293T cells were seeded at a den-
sity 8 ×  106  cells per 10  cm dish and grown in DMEM 
(high glucose, 4.5  g/L) supplemented with 10% FBS. 
12–16 h after the initial plating, culture media were dis-
carded and replaced with 12  mL of pre-warmed growth 
medium (DMEM with 10% FBS). HEK293T cells were 
transfected with 30 μg of plasmid DNA (15 μg of transfer 
vector, 10 μg of packaging plasmid and 5 μg of envelope-
encoding plasmid) using linear polyethylenimine (PEI, 
25 kDa, Polysciences, Warrington, PA, USA) at 2:1 PEI to 
DNA ratio. One day after transfection, culture media were 
replaced with fresh ones, and additionally supplemented 
with 10 mM HEPES buffer (pH = 7.2). Cell supernatants 
containing lentiviral particles were harvested after 24 and 
48 h. Cellular debris was removed from the supernatants 
by centrifugation (2000G, 5 min) and filtration through a 
0.45 μm PES (low protein binding) filter. Afterwards, len-
tiviral particles were concentrated by ultrafiltration with 
100 kDa cut-off Amicon centrifugal filter (EMD Millipore, 
Billerica, MA, USA), aliquoted and stored at −80 °C.
Lentiviral transduction of iPS cells
In order to create pluripotent lines expressing Tet-On 
transactivator gene, iPS cells were seeded in low den-
sity on Geltrex-coated (20  μg/cm2) 6-well plates and 
cultured in Essential 8 medium. After 24 h, the medium 
was changed and approximately 100 transduction units 
of lentiviral particles prepared from pLVX-EF1α-Tet3G 
transfer plasmid (Clontech) was added to the culture 
medium. After 2  days, the medium of transduced iPS 
cells was changed to Essential 8 medium supplemented 
with 50  μg/mL of G418 (Life Technologies). Cells were 
maintained in selection medium until non-transduced 
iPS cells in control well were no longer detected on the 
plate. G418 resistant iPS cell colonies carrying Tet-On 3G 
transactivator gene were picked and expanded around 
day 10 post transduction.
To establish iPSC lines carrying Pdx1 and Nkx6.1 
transgene under the control of doxycycline-inducible 
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promoter, iPSC line with stably integrated Tet-on 3G 
regulatory gene were seeded at low density on Geltex-
coated 6-well plate. Next day, cells were transduced with 
lentiviral vectors carrying either Pdx1-VP16 or Nkx6.1, 
or the combination of both under the control of doxy-
cycline-regulated TRE3GV promoter. 2  days after the 
transduction culture medium was supplemented with 
20  ng/mL of Puromycin (InvivoGen), and iPS cell colo-
nies were maintained in antibiotic-containing media until 
non-transduced cells were no longer observed in con-
trol wells. 7 days post transduction, puromycin-resistant 
iPSC colonies were isolated, expanded and examined for 
doxycycline-induced transgene expression.
Alkaline phosphatase staining
Cells were fixed with 4% PFA in PBS for 20  min. Then, 
they were washed with TBS twice and stained with 
5-bromo-4-chloro-3-indolylphosphate (BCIP) and nitro-
blue tetrazolium (NBT) substrate solution (0.02% BCIP, 
0.03% NBT, 5  mM MgCl2 in 150  mM TBS, pH 9.5) at 
37 °C until the purple colour emerged, washed with dis-
tilled water, and dried.
Flow cytometry
HeLa cells transfected with pCXB-EmGFP plasmid were 
analysed for green fluorescent protein expression by flow 
cytometry. 2 days after transfection, cells were detached 
from cell culture vessels to a single-cell suspension with 
TrypLE Select (Life Technologies) and analysed using 
Amnis FlowSight flow cytometer (EMD Millipore). The 
acquisition was set for 70,000 events per sample, and 
the data were analysed using IDEAS software (EMD 
Millipore).
xCELLigence impedance analysis of cells growth 
and survival
The RTCA xCELLigence (Roche, Basel, Switzerland) was 
used to determine cell viability. 150 μL of prepared cul-
ture medium was added into each well of E-plate 16. The 
background impedance was measured for 60  s. Fibro-
blasts and renal epithelial cells were grown on tissue cul-
ture vessels prior to the experiment. After reaching 50% 
confluence, they were rinsed with PBS, and detached 
from plates by treating them with Accutase. Single cell 
suspension was prepared and the cells were counted on 
ADAM-MC Cell System (NanoEnTek, Seoul, Korea). The 
cell suspension was added to medium-containing wells 
on E-plate  16 to final density 10,000  cells per well. The 
adhesion and cell viability was monitored every 60  min 
for a period of up to 72 h. The electrical impedance was 
quantified by the RTCA system as Cell index (CI) val-
ues. As the electrical impedance depends on the number 
of cells attached to the electrode and the dimensional 
changes of the attached cells, CI values represented phys-
iological state of analysed cells.
Immunofluorescence analysis
For immunofluorescence studies, cells were fixed for 
20  min at room temperature with 4% paraformalde-
hyde (PFA) in PBS, and washed once with TBS-T (Tris-
buffered 0.9% saline with 0.05% of Tween-20, pH = 7.2). 
After fixation, cells were permeabilized (for 10 min with 
TBS-T/0.25% Triton X-100) and blocked with 10% don-
key serum in TBS-T. Cells were incubated with primary 
antibody (1  h, room temperature), washed three times 
with TBS-T and incubated for 1 h at room temperature 
with Alexa-conjugated secondary antibodies (Life Tech-
nologies) and 4′,6-diamidino-2-phenylindole (DAPI) 
(50  ng/ml). Coverslips were mounted in 10% polyviny-
lalcohol in 25  mM Tris–HCl (pH 8.7) with 5% glycerol 
and 2.5% 1,4-diazobicyclo[2,2,2]-octane. Samples were 
examined on an Eclipse Ci-S epifluorescence microscope 
equipped with a DS-5Mc colour CCD camera (Nikon, 
Tokyo, Japan). Images in blue channel (350/50ex, 400lp, 
460/50em), green channel (480/40ex, 510lp, 535/50em), 
and red channel (560/40ex, 585lp, 630/75em) were 
acquired with NIS-Elements 4.0 and processed with 
ImageJ software. Antibodies used for immunofluores-
cence analysis are listed in Additional file 2: Table S2.
Dithizone stainings
Dithizone stock solution was prepared from 10  mg of 
dithizone dissolved in 10 mL of DMSO. Cells on the cul-
ture dish were fixed with 4% PFA for 15 min at room tem-
perature, rinsed with TBS-T and stained with dithizone 
working solution (1:100 dilution of the stock in PBS) for 
30 min at 37 °C. After that, cells were washed two times 
with PBS and examined under a microscope.
Quantitative real time PCR
Total RNA was isolated with a NucleoSpinTriPrep kit 
(Macherey–Nagel, Düren, Germany) according to manu-
facturer’s protocol. Concentration of nucleic acid samples 
was measured spectrophotometrically (NanoPhotometer, 
Implen, Germany) and 250 ng of RNA was reverse-tran-
scribed using random hexamer primers and M-MuLV 
reverse transcriptase according to manufacturer’s speci-
fications (New England Biolabs). 50 ng of cDNA template 
along with 200  nM of primer and 6  μL of SYBR Select 
Master Mix (Life Technologies) was used in reaction. 
Primer sequences are listed in Additional file 3: Table S3. 
Quantitative real-time PCR was performed on StepO-
nePlus™ Real-Time PCR System (Applied Biosystems, 
Foster City, CA, USA). In order to confirm the speci-
ficity of amplification, the melting curve was analysed 
in each case using StepOne™ Software v2.2.2 (Applied 
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Biosystems). Normalized relative expression level was 
calculated utilizing the method described previously by 
Pfaffl [21] based on sample’s average CT value and PCR 
efficiency.
Differentiation of iPSC into insulin producing cells
The protocol of iPSC differentiation into insulin produc-
ing cells was based on the modified procedure described 
by Kunisada et al. [13]. Definitive endoderm was obtained 
using the following method. iPS cells with genetically 
introduced transgenes were seeded onto a 6-well plate 
covered with Geltrex or Vitronectin. Cells were main-
tained in Essential 8 medium for the next 4  days (with 
daily medium exchange) until they reached 70–80% of 
confluence. Then, the culture medium was changed to 
RPMI-1640 supplemented with 100  ng/mL of Activin 
A, 3 μM of CHIR99021 and 2% foetal bovine serum. iPS 
cells were maintained in abovementioned medium for 
24  h to initiate the differentiation towards endodermal 
lineage. Afterwards, cells were incubated in RPMI-1640 
basal medium supplemented with 100 ng/mL of Activin 
A and 2% of FBS for the next 2 days.
Definitive endoderm obtained in such manner was fur-
ther differentiated in iMEM medium supplemented with 
10  μM SB431542, 1  μM dorsomorphin, 2  μM retinoic 
acid and 1% of B27 or defined NS21 supplements (R&D 
Systems, Minneapolis, MN, USA). The cells were cul-
tured in this medium for 7 days with medium exchange 
every other day. After that, cells were incubated in iMEM 
containing 10  μM forskolin, 10  μM dexamethasone, 
10 μM nicotinamide, 5 μM Alk 5 inhibitor II and 1% of 
medium supplement (B27 or NS21). In order to induce 
TET promoter-controlled transgene expression, 10  ng/
mL of doxycycline was added do the IPC differentiation 
media either through stage III or through stages III and 
IV.
ELISA assays
Cells grown in culture conditions inductive for pancre-
atic islets specification were preincubated in L15 medium 
without insulin and supplemented with 2.5  mM glu-
cose in 37  °C for 4  h. Supernatants were collected, fil-
tered through 0.45 µm filter and used for determination 
of insulin secretion. For ELISA experiments, wells of 
96-well plate (Human Insulin ELISA kit, Sigma-Aldrich) 
coated with antibodies against human insulin were incu-
bated with 100  µL of analysed supernatants along with 
insulin concentration standards run in parallels, for 2.5 h 
with gentle shaking. The whole assay was performed at 
room temperature. After the incubation, solutions were 
discarded and wells were rinsed three times with 1× 
Wash buffer. Afterwards, 100 µL of the detection buffer 
containing biotinylated antibodies was applied to each 
well and incubated for 1 h. After the washing step (three 
times with 1× Wash buffer), bound antibodies were 
detected with streptavidin-conjugated horse-radish per-
oxidase (100  µL of the solution with 45  min of incuba-
tion). The reaction was visualised by incubation with 
100 µL of colorimetric TMB substrate (30 min, develop-
ment was ended with 50 µL of Stop solution. Absorbance 
was determined spectrophotometrically at 450  nm on 
NanoPhotometer (Implen).
Statistical analyses
The reprogramming assays, xCELLigence, qPCR and 
ELISA experiments were carried out at least three times 
and presented as the average values  ±  SEM (standard 
error of the mean). Difference between samples was com-
pared by the two-tailed Student’s t test and was consid-
ered significant at p < 0.05.
Results
Reprogramming of somatic cells to pluripotent state 
in defined culture conditions
Generation of pluripotent stem cells in conditions that 
ensure reproducible induction, expansion and their 
controllable directed differentiation is an indispensable 
requirement for their therapeutic application. Clinically-
relevant iPS cells and differentiated derivatives need to 
be obtained and maintained in fully defined culture con-
ditions. For this purpose, we aimed to optimize somatic 
cells culture as well as the step of reprogramming vec-
tors delivery. Different cell culture media were prepared 
according to compositions shown in Additional files 4 
and 5: Tables S4 and S5, and evaluated for their ability 
to sustain growth of the initial somatic cells. In addition, 
as control, we tested medium containing foetal bovine 
serum and commercially available growth media. The 
impact of medium composition was tested using xCEL-
Ligence system that monitors cell proliferation. As shown 
in Fig.  2a, HFF-1 fibroblasts showed the highest prolif-
eration rate in medium F#3 that contained recombinant 
albumin, transferrin, EGF, FGF2, PDGF-AB as well as 
hydrocortisone, sodium selenite and lipid concentrate. 
For renal epithelial cells, defined medium Ep#5 (contain-
ing albumin, transferrin, insulin, EGF, FGF2, PDGF-AB, 
epinephrine, triiodo-l-thyronine, sodium selenite and 
chemically defined lipids) provided the highest prolifera-
tion rate. However, it needs to be noted that serum-con-
taining media outperformed all abovementioned media 
in terms of their effect on cell survival and growth.
Since previously used transfection reagent, FuGENE 
6 (Promega, Madison, WI, USA) has undisclosed com-
position, we sought the chemically defined alternative. 
Recently, copolymer of low-weight polyethylenimine 
(PEI) and Pluronic polymers has been reported as a 
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low-toxic and efficient DNA delivery agent in estab-
lished cell lines and primary cells [20]. As the L64-PEI 
(PCM-04) polymer was not commercially available we 
conducted conjugation of PEI (MW = 1200 Da) to PEG-
PPG-PEG block polymer (pluronic L64, MW = 2900 Da) 
and evaluated its potential as a plasmid delivery carrier. 
HeLa cells were transfected with pCXB-EmGFP plas-
mid expressing optimized GFP protein under control of 
CAGGS promoter using synthesised L64-PEI reagent at 
1:3 plasmid to polymer weight ratio. Transfection effi-
ciency was monitored by flow cytometry and epifluo-
rescence microscopy. As shown in Fig.  3b, the number 
of GFP-positive cells reached 12.8% for cells transfected 
with L64-PEI, whereas FuGENE 6 transfection reagent 
provided ~4 times higher efficiency.
In order to better understand the composition of the 
minimal constituents necessary for the acquisition of 
pluripotent state by reprogrammed somatic cells, we 
address the question of the applicability of different 
protein components of extracellular matrix on the effi-
ciency of pluripotent cells induction. For this purpose, 
cell culture vessels were coated with murine proteins 
secreted by Engelbreth-Holm-Swarm (EHS) sarcoma 
cells (Geltrex, 45  μg/cm2), human recombinant Vitron-
ectin (1  μg/cm2), porcine gelatin (1  μg/cm2), human 
recombinant Laminin-511 (1  μg/cm2), human recombi-
nant Laminin-521 (1 μg/cm2), human fibronectin (0.5 μg/
cm2), human recombinant Collagen I (5 μg/cm2), human 
Collagen IV (5 μg/cm2) and fractions of laminins isolated 
from EHS tumour (1 μg/cm2). Induced pluripotent stem 
cells were derived from adult exfoliated renal epithelial 
cells and HFF-1 neonatal fibroblasts. These cells were 
seeded on protein-coated 6-well plates at density 20,000 
cells per well (for renal epithelial cells) or 80,000 cells per 
well (in case of fibroblasts) and transfected with oriP/
EBNA-1 episomes as described previously [17]. Repro-
gramming experiments were carried out for 3–4 weeks till 
the emergence of compact, tightly packed ESC-like colo-
nies which were fixed with paraformaldehyde and evalu-
ated for the alkaline phosphatase activity. The exemplary 
phosphatase stainings along with the iPSC colony forming 
efficiencies in fibroblasts and epithelial cells are presented 
in Fig.  3. The highest efficiencies of reprogramming of 
fibroblasts were obtained in case of Laminin-511 (0.08%) 
and Laminin-521 (0.07%), whereas for human renal 
epithelial cells the most efficient reprogramming was 
achieved with Geltrex matrix (1.1%), but also with human, 
recombinant type I Collagen (0.8%). Altogether, our 
results confirmed that pluripotency can be induced with 
application of defined and xeno-free protein components.
Fig. 2 Optimisation of somatic cells culture conditions and transgenes delivery. a Cell number was monitored by xCELLigence system. 6000 of epi‑
thelial cells or fibroblasts were seeded on one well of the assay plate and maintained in corresponding culture media. Their impact on cell growth 
was monitored for 72 h and cell index (CI) values at the end of experiment are presented as a mean of three independent counts. b Comparison of 
transfection efficiencies obtained with use of FuGENE 6 reagent and synthesized L64‑PEI copolymer. The expression plasmid pCXB‑EmGFP was tran‑
siently introduced into HeLa cells. Transfection with both reagents was carried out in the presence of FBS and two days later, transfection efficiency 
was assessed by flow cytometry and fluorescence microscope. Scale bar 100 μm
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Finally, to evaluate polymer utility in derivation of 
induced pluripotent cells on defined ECM constituents, 
we plated HFF-1 fibroblasts and urinary epithelial cells 
on culture vessels coated with recombinant human Col-
lagen I and Laminin-511, respectively. One day later, cells 
were transfected with 2  μg of episomal plasmids using 
L64-PEI reagent. The transfection was repeated 24 h later 
and cells were maintained in TeSR-E7 medium for next 
2  weeks. After that, the culture medium was replaced 
with Essential 8 medium and cells were retained for 
next 2–3 weeks until the emergence of ESC-like, tightly-
packed, clustered colonies. At the end of the experiment, 
culture plates were fixed with PFA and stained for alka-
line phosphatase activity (Additional file  6: Figure S1). 
The reprogramming efficiencies reached 0.01% for fibro-
blasts and 0.08% for renal epithelial cells.
Taken together, our results clearly demonstrate that 
induced pluripotent stem cells can be generated from 
human somatic cells using fully defined, xeno-free 
protocols.
Formation of definitive endoderm in the absence 
of animal‑derived components
iPSC were differentiated into definitive endoderm cells 
using activators of TGFβ and Wnt signalling path-
ways. Cells were incubated for 24  h in RPMI1640 basal 
medium containing 100  ng/mL of Activin A and 3  μM 
CHIR99021. Next, cells were maintained in culture for 
2  days in RPMI1640 medium with Activin A. In addi-
tion, these media were supplemented with serum or its 
replacements to extend lifespan of cells. Four culture 
media were prepared according to compositions shown 
in Additional file 7: Table S6. Formulated differentiating 
media contained 2% of bovine (DE1) or human serum 
(DE2) or in case of DE3 and DE4 media contained a 
mixture of various defined additives, deprived from the 
serum. The influence of these media on the process of 
definitive endoderm formation was studied by qPCR 
measurements and immunocytochemical stainings. Lev-
els of mRNA encoding protein markers characteristic for 
endoderm (SOX17, FOXA2, CXCR4) were analysed and 
Fig. 3 Reprogramming of human fibroblastic and epithelial cells into iPS cells with application of different protein components of the extracellular 
matrix. a Efficiencies of generation of iPS cells obtained from renal epithelial cells. b Colony forming efficiencies in the course of fibroblast repro‑
gramming into iPS cells. c Exemplary results of alkaline phosphatase staining on iPS cells generated from renal epithelial cells grown on cell culture 
vessels coated with different proteins and extracellular matrix components
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are presented in Fig. 4a, along with raw data included in 
Additional file  8: Table S7. The highest relative expres-
sion of marker genes was observed for FBS-containing 
medium DE1 and defined medium DE4, that included 
recombinant albumin, insulin, transferrin as well as 
ascorbic acid and chemically defined lipids.
Presence of definitive endoderm markers was evalu-
ated on protein level as well, using antibodies against 
Fig. 4 Differentiation of pluripotent cells into definitive endoderm cells. a Expression of genes characteristic for definitive endoderm (CXCR4, FOXA2, 
SOX17) for examined differentiation protocols relative to undifferentiated iPSC samples. For the differentiation experiments cells were maintained in 
basal medium (RPMI‑1640) with Activin A and CHIR99021 for 24 h, and in medium with Activin A alone for the next 48 h. In addition, the media con‑
tained: DE1—foetal bovine serum, DE2—human serum, DE3—insulin, transferrin and sodium selenite, DE4—albumin, insulin, transferrin, defined 
lipids concentrate and ascorbic acid. b Results of immunocytochemical analysis of the generated definitive endoderm cells showing cells positive 
for CXCR4 and SOX17 markers, and clusters of cells displaying E‑cadherin expression. Cells were prepared as described in a. Scale bar 50 µm
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E-cadherin, CXCR4 and SOX17. Results of immunocy-
tochemical analysis are shown in Fig.  4b. For all tested 
media we detected cells with cytoplasmic presence of 
CXCR4, SOX17 localized in cell nuclei, as well as clusters 
of cells positive for E-cadherin.
Collectively, these results indicate that in terms of the 
efficiency and endodermal markers expression, the defin-
itive endoderm can be formed without animal-derived 
products at level comparable to culture conditions where 
serum was included.
Insulin secretion is enhanced by PDX1 and NKX6.1 
induction during IPC progenitors’ maturation
In this study, two strategies for generation of insulin pro-
ducing cells were coupled. First method involves forced 
expression of specific transcription factors in differenti-
ating cells. The second approach includes differentiation 
of initial stem cells by activation or inhibition of certain 
signalling pathways by small chemical molecules and 
protein ligands.
To analyse the impact of Pdx1 and Nkx6.1 transcription 
factors on the process of derivation of insulin producing 
cells, we generated doxycycline-regulated pluripotent 
cell lines. For this purpose, iPS cells were transduced 
with lentiviral vector carrying Tet-On 3G transactiva-
tion gene. After the negative selection with G418, these 
cells were again transduced with lentiviral particles car-
rying PDX1-VP16 and NKX6.1 coding sequences under 
the control of the TRE3G promoter. Following selection 
with puromycin antibiotic, positive colonies with stably 
integrated constructs were collected and evaluated for 
inducible expression by doxycycline. Induced and control 
samples were analysed by immunocytochemical stainings 
as shown in Fig. 5a.
Established regulated cell lines were differentiated into 
definitive endoderm, and further to pancreatic progeni-
tors through the 1 week of incubation in iMEM medium 
with addition of 1% of B27 or NS21 supplements, 2 μM 
retinoic acid, 10  μM SB431542, and 1  μM dorsomor-
phin. For maturation of insulin producing cells, the 
culture medium was changed to iMEM basal medium 
supplemented with 1% of NS21, 10 μM forskolin, 10 μM 
dexamethasone, 10  μM nicotinamide and 5  μM Alk 5 
inhibitor II. Cells were maintained in these conditions for 
7 days. Expression of PDX1-VP16 and NKX6.1 transgenes 
or combination of both was induced by including doxy-
cycline in medium for pancreatic progenitors and/or in 
medium for pancreatic islets specification as shown on 
diagram in Fig. 1. To evaluate the ability of obtained cells 
to secrete insulin, IPC cells were incubate in L15 medium 
supplemented with 2.5  mM glucose. The secretion of 
insulin hormone was measured with ELISA assay, nor-
malized for total protein concentration and presented in 
Fig. 5b. The presence of insulin and C-peptide in estab-
lished IPC was evaluated by immunocytochemical analy-
sis and shown in Fig. 5c.
In order to further determine the identity of differenti-
ated cells, we performed immunocytochemical analysis 
using antibodies characteristic for β-cells and pancreatic 
lineage. iPSC lines expressing PDX1-VP16, NKX6.1 and 
combination of both factors from the doxycycline-regu-
lated promoter were differentiated into insulin produc-
ing cells. Expression of transgenes was induced either 
on the stage of generation of IPC progenitors or during 
maturation of insulin producing cells. Results of experi-
ments shown in Fig.  6 revealed in all studied samples 
the presence of cell clusters positive for MafA, Pax6, 
SLC30A8 and Tyrosine hydroxylase. With use of Somato-
statin-specific antibodies we could detect single hormone 
expressing cells among differentiated cell populations. 
In addition to SLC30A8 protein detection in ICC assay, 
we performed stainings with dithizone, a zinc-chelating 
agent, which indicated the presence of functional zinc 
transporter ZnT8 in obtained insulin producing cells.
Altogether, generated cells were shown to secrete insu-
lin into the culture medium and displayed molecular 
markers of pancreatic cells. However, the highest insu-
lin concentration was detected in case of cells with tran-
scription factors induction at stage IV (maturation of 
Insulin Producing Cells). Furthermore, cells expressing 
both PDX1-VP16 and NKX6.1 secreted higher level of 
the hormone, regardless the induction time point.
Discussion
Regulatory issues related to cell-based therapies are get-
ting broadened to acknowledge treatments with use of 
stem cells and products of their differentiation. Although 
few clinical trials based on application of differentiated 
embryonic stem cells have been approved, there are still 
safety concerns that need to be thoroughly addressed. 
These include among others, derivation of pluripotent 
stem cells, identity and homogeneity of clinically-rele-
vant cells and their immunogenic potential. The last issue 
can be resolved by usage of either patient-specific or 
allogenic, HLA-matched iPSC further differentiated into 
required cells. Establishment of fully defined conditions 
of iPSC generation and differentiation would settle some 
of the abovementioned concerns and therefore be a step 
towards putting these cells closer to clinical applications.
In this work we made an attempt to generate induced 
pluripotent cells and differentiate them into insulin pro-
ducing cells. Development of reproducible protocols for 
differentiation of iPSC into specified multipotent pro-
genitors and terminally differentiated cells remains chal-
lenging. In particular, the application of components 
originating from animals for manufacturing of cells for 
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therapeutic use pose several problems due to batch-to-
batch variation and the inherited inconsistency of ani-
mal-derived products. Additional concerns involve the 
contamination with adventitious agents that may result in 
animal-to-human pathogen transmission in the course of 
therapy. As a consequence, there is a high demand from 
regulatory bodies such as Food and Drug Administra-
tion (FDA) and the European Medicines Agency (EMA) 
to put restrictions on the application of animal products 
in cell-based therapeutics [22, 23]. For this reason, our 
aim was to establish efficient and reliable protocols based 
on defined components. In the first part of our work, 
we evaluated the ability of different extracellular matrix 
(ECM) constituents to support induction of pluripotency 
in reprogrammed somatic cells. We tested recombinant 
or xeno-free Vitronectin, Fibronectin, Laminins and Col-
lagens, and compared them with undefined matrices. 
Although, some of these proteins were reported to main-
tain pluripotency markers in already established iPSC or 
ESC lines [24–28], they were not evaluated in the system-
atic manner for induction of pluripotency.
Our results demonstrated that iPSC colonies could be 
obtained on all tested matrix components, including pre-
cisely defined protein constituents, although with vary-
ing efficiencies. Neonatal fibroblasts were reprogrammed 
with highest efficiencies on recombinant Laminin-511 
and Laminin-521. These proteins were detected on 
human embryonic stem cells and it is presumed that 
Fig. 5 Insulin and C‑peptide synthesis by generated insulin producing cells. a Doxycycline‑regulated Pdx1 and Nkx6.1 expression. iPSC lines with 
stably integrated Pdx1 and Nkx6.1 transgenes under control of Tre3G promoter were induced by addition of doxycycline and stained with antibod‑
ies against Pdx1 and Nkx6.1. The negative control were iPS cells that were not treated with doxycycline. Scale bar 100 µm. b Insulin secretion in 
response to 2.5 mM glucose concentration after transgenes induction at selected steps of the differentiation procedure. Results of the ELISA were 
normalized to the total protein concentration and presented as picograms of produced insulin per milligram of the total protein content of insulin 
secreting cells. Control includes cells without introduced transgenes. Asterisk indicate statistically relevant difference between compared samples. 
c Immunocytochemical detection of insulin and C‑peptide production in cells where transgene expression was switched on at indicated stages of 
differentiation. Scale bar 20 µm
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they play a role in maintaining intrinsic properties of 
pluripotent stem cells [25]. In particular, the globular 
domain of laminins interact with α6β1 integrins present 
on cell membrane. This activates PIK3CA/AKT signal-
ling pathway, which influence numerous cytophysiologi-
cal processes including their self-renewal ability [29, 30]. 
Although its precise mechanisms remains elusive, the 
interaction responsible for cell proliferation may trig-
ger signalling events that influence transcriptional status 
and reprogramming rate of fibroblasts [26, 31]. Integ-
rins serve as connectors for cell-to-cell and cell-to-ECM 
interactions. These heterodimeric transmembrane recep-
tors consists of α and β subunits, which can make up to 
24 different integrin combinations. Different receptor 
variants have affinities for specific ECM components; for 
instance, integrin αVβ5 interacts with vitronectin, α5β1 
with fibronectin and α6β1 integrin binds to laminins [32]. 
On the other hand, there is also an interplay between 
iPSC generation and expression of particular integrin 
receptors, as the Oct3/4 and Sox2 transcription factors 
bind to regulatory regions of α6 and β1 subunits cod-
ing sequences [33, 34], and during reprogramming of 
fibroblasts into iPS cells, the expression of α6 subunit is 
upregulated within 3  days after fibroblast transduction 
with retroviruses carrying reprogramming factors [35]. 
Conversion of renal epithelial cells into iPSC was the 
most effective on Geltrex matrix and recombinant Col-
lagen I. Geltrex is a compound matrix comprising dif-
ferent proteins secreted by EHS sarcoma cells including 
laminins, entactin and collagens. Notably, Collagen type 
Fig. 6 Structural and functional characterisation of established IPCs. Results of immunocytochemical and colorimetric characterisation of gener‑
ated insulin producing cells. Pluripotent cell lines with stably introduced PDX1‑VP16 and NKX6.1 transgenes were differentiated towards insulin 
producing cells. Transgenes expression was switched on by doxycycline at the stage of IPC progenitors or maturation of insulin producing cells. 
Differentiated cells were immunophenotyped with antibodies against MafA, Pax6, SLC30A8, somatostatin, tyrosine hydroxylase (all except TH coun‑
terstained with DAPI), and stained with dithizone. The images represent selected clusters of positive cells in the population of differentiated cells. 
Scale bar 100 µm
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I and IV is thought to influence stem cells self-renewal, 
as their binding to integrin α2β1 and DDR1 receptor [36] 
activates Bmi-1 protein involved in cell proliferation [37].
In our attempt to establish fully defined conditions for 
generation of induced pluripotent cells we used copoly-
mer of low-weight polyethylenimine and PEG-PPG-
PEG block polymer (pluronic L64). This compound was 
developed by Wang and co-workers [20] for DNA deliv-
ery applications. In our studies we successfully delivered 
episomal reprogramming plasmids into human cells of 
epithelial and fibroblastic origin achieving iPSC forma-
tion rate comparable to the previously used commercially 
available transfection reagent [17].
The definitive endoderm (DE) is formed during gas-
trulation and participates in morphogenesis of digestive 
tract including stomach, small and large intestine, liver 
and pancreas, and it can also contribute to development 
of lungs, thymus and thyroid. DE formation is induced 
by activation of TGFβ and Wnt signalling pathways. In 
the in  vitro experimental setup, the presence of Activin 
A and Wnt3a or inhibitors of GSK3β is essential for the 
establishment of definitive endoderm. In most of availa-
ble protocols varying concentrations of FBS were used as 
the absence of serum was reported to severely restrict the 
induction of DE or results in poor cell survival [38–40]. 
In this work we sought to replace FBS in order to estab-
lish defined conditions for DE cells generation. Our data 
clearly indicate that a combination of recombinant albu-
min, insulin, transferrin as well as lipid concentrate and 
ascorbic acid is as efficient in definitive endoderm induc-
tion as FBS or human serum and is sufficient to substi-
tute them.
Pancreas develops from endoderm of the anterior 
intestine upon signalling through the specific receptors, 
which in turn activates the network of transcription fac-
tors necessary for differentiation of endocrine cells. The 
pancreas is formed from the fusion of the dorsal and 
ventral pancreatic ducts. The pancreatic buds appear at 
about 25th day of human gestation arising from the dis-
tal foregut endoderm. Development of insulin producing 
cells begins at the end of the embryonic period around 
day 56 post-conception, when the number of insulin-
positive cells starts to gradually increase. The Langerhan’s 
islets are formed in the first trimester of the pregnancy 
about 12  week of the gestation [41]. All of these events 
are triggered by nearby cells and tightly controlled. Sig-
nals driving formation of dorsal bud involve release of 
FGF2 and Activin β from the notochord cells, and they 
are implicated in inhibition of the Hedgehog pathway 
in epithelial cells forming the dorsal bud (reviewed in 
[42]). During endocrine cell development, Notch signal-
ling plays an important role in maintaining the balance 
between the expansion of progenitor cells and their 
differentiation into mature cell types. Its downstream 
target, Hes-1 influences transcription of Ngn3, which is 
a key activator of endocrine pancreas commitment [43]. 
Pdx1 is one of the first transcription factors expressed 
in foregut endoderm and its requirement for pancreas 
development is evident from the knock-out studies that 
resulted in the absence of pancreas at birth [44]. The 
transcription factor is essential for the development of 
insulin producing cells, as Pdx1 regulates insulin pro-
duction in glucose-dependant manner. The mRNA level 
of Pdx1 declines in fully developed endocrine cells, and 
the factor expression is restricted to mature β-cells [45]. 
Nkx6.1 is another transcription factor that was found 
to be specific for adult insulin producing cells [46]. This 
factor controls gene regulatory network necessary for 
establishment of beta cell identity. In addition, Nkx6.1 is 
involved in lineage specification in early pancreatic pro-
genitor tissue as it has been found to repress the commit-
ment of the endocrine progenitors to non-beta cells [15].
In this work, we analysed the influence of induced 
expression of the two abovementioned factors, Pdx1 and 
Nkx6.1 and their concurrent activation on the process of 
differentiation of human pluripotent stem cells towards 
insulin producing cells. The effect of Pdx1 exogenous 
expression on differentiation or transdifferentiation pro-
cesses of various cells into IPCs was previously reported, 
either as a sole introduced factor [47–49] or in combina-
tion with NeuroD1 and MafA [50], but not with Nkx6.1. 
Our results demonstrate for the first time that differences 
in insulin secretion depend on the differentiation stage 
at which transcription factors expression was induced. 
Notably, the highest insulin production was obtained 
in case of simultaneous activation of both transgenes 
throughout maturation of insulin producing cells. Anal-
ysis of MafA PAX6, SLC30A8, Tyrosine Hydroxylase, 
Somatostatin, as well as functional assay of ZnT8, did 
provide evident insight into the mechanism responsible 
for the difference between stage III and stage IV cells abil-
ity to produce insulin. The selected transcription factors 
play critical role in development and proper functioning 
of pancreas since mutations in genes encoding these fac-
tors or alterations in their expression are associated with 
diseases and multitude of developmental abnormalities 
[51–53]. Pdx1 and Nkx6.1 control expression of a num-
ber of pancreas-related genes [15, 54]. Therefore, it is dif-
ficult to identify the precise molecular mechanisms that 
are responsible for the observed results. However, one 
could hypothesise that the overexpression of these fac-
tors at the stage of maturation of insulin producing cells 
can interfere with signalling pathways responsible for 
establishment of such cells. As in the process of embryo-
genesis, varying expression of certain genes leads to the 
formation of all types of hormone-releasing islet cells [55, 
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56], one may conclude that the forced expression of Pdx1 
and Nkx6.1 can shift the developmental balance toward 
the increased formation of insulin producing cells. More-
over, it seems that simultaneous expression of both fac-
tors enhances the emergence of beta cell-like cells, as the 
obtained cells share more characteristic features with 
cells of native pancreatic islets, particularly in the level of 
insulin secretion.
Conclusions
In this work, insulin producing cells were generated from 
induced pluripotent stem cells in defined culture condi-
tions. Stem cells were differentiated by culture in media 
containing small chemical molecules and recombinant 
proteins with concurrent overexpression of specific tran-
scription factors at different steps of IPC formation. Our 
results indicate that it is possible to obtain insulin pro-
ducing cells in fully defined culture setup that is free from 
animal-derived components, which is essential for the 
prospective clinical applications. In addition, we dem-
onstrated that induced expression of PDX1 and NKX6.1 
genes, which encode transcription factors indispensable 
for pancreatic development, at the stage of maturation of 
IPSC enhances production of insulin. Furthermore, the 
concurrent induction of both factors in the course of the 
differentiation process results in highest level of secretion 
of the hormone.
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